Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs.

Sherger M, Kisseberth W, London C, Olivo-Marston S, Papenfuss TL.

BMC Vet Res. 2012 Oct 31;8:209. doi: 10.1186/1746-6148-8-209.

2.

Myeloid-derived suppressor cells in breast cancer.

Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd.

Breast Cancer Res Treat. 2013 Jul;140(1):13-21. doi: 10.1007/s10549-013-2618-7. Epub 2013 Jul 5. Review.

3.

Myeloid-derived suppressor cell heterogeneity in human cancers.

Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V.

Ann N Y Acad Sci. 2014 Jun;1319:47-65. doi: 10.1111/nyas.12469. Review.

PMID:
24965257
4.

Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients.

Jiang J, Guo W, Liang X.

Hum Immunol. 2014 Nov;75(11):1128-37. doi: 10.1016/j.humimm.2014.09.025. Epub 2014 Oct 7. Review.

PMID:
25305034
5.

Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Albeituni SH, Ding C, Yan J.

Cancer J. 2013 Nov-Dec;19(6):490-501. doi: 10.1097/PPO.0000000000000006. Review.

6.

MDSCs in cancer: Conceiving new prognostic and therapeutic targets.

De Sanctis F, Solito S, Ugel S, Molon B, Bronte V, Marigo I.

Biochim Biophys Acta. 2016 Jan;1865(1):35-48. doi: 10.1016/j.bbcan.2015.08.001. Epub 2015 Aug 6. Review.

PMID:
26255541
7.

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH.

Crit Rev Oncol Hematol. 2011 Jan;77(1):12-9. doi: 10.1016/j.critrevonc.2010.02.004. Epub 2010 Mar 20. Review.

8.

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.

Diaz-Montero CM, Finke J, Montero AJ.

Semin Oncol. 2014 Apr;41(2):174-84. doi: 10.1053/j.seminoncol.2014.02.003. Epub 2014 Feb 14. Review.

9.

Complexity and challenges in defining myeloid-derived suppressor cells.

Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S.

Cytometry B Clin Cytom. 2015 Mar;88(2):77-91. doi: 10.1002/cyto.b.21206. Epub 2014 Dec 12. Review.

10.

Drafting the proteome landscape of myeloid-derived suppressor cells.

Gato M, Blanco-Luquin I, Zudaire M, de Morentin XM, Perez-Valderrama E, Zabaleta A, Kochan G, Escors D, Fernandez-Irigoyen J, SantamarĂ­a E.

Proteomics. 2016 Jan;16(2):367-78. doi: 10.1002/pmic.201500229. Epub 2015 Dec 14. Review.

PMID:
26403437
11.

Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.

Botta C, GullĂ  A, Correale P, Tagliaferri P, Tassone P.

Front Oncol. 2014 Dec 8;4:348. doi: 10.3389/fonc.2014.00348. eCollection 2014. Review.

12.

Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.

Katoh H, Watanabe M.

Mediators Inflamm. 2015;2015:159269. doi: 10.1155/2015/159269. Epub 2015 May 19. Review.

13.

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Marvel D, Gabrilovich DI.

J Clin Invest. 2015 Sep;125(9):3356-64. doi: 10.1172/JCI80005. Epub 2015 Jul 13. Review.

14.

Myeloid derived suppressor cells in chronic myeloid leukemia.

Giallongo C, Parrinello N, Brundo MV, Raccuia SA, Di Rosa M, La Cava P, Tibullo D.

Front Oncol. 2015 May 15;5:107. doi: 10.3389/fonc.2015.00107. eCollection 2015. Review.

15.

Immature myeloid-derived suppressor cells: A bridge between inflammation and cancer (Review).

Musolino C, Allegra A, Pioggia G, Gangemi S.

Oncol Rep. 2017 Feb;37(2):671-683. doi: 10.3892/or.2016.5291. Epub 2016 Dec 5. Review.

PMID:
27922687
16.

Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate.

Meirow Y, Kanterman J, Baniyash M.

Front Immunol. 2015 Oct 12;6:523. doi: 10.3389/fimmu.2015.00523. eCollection 2015. Review.

17.

Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.

Chesney JA, Mitchell RA, Yaddanapudi K.

J Leukoc Biol. 2017 May 25. pii: jlb.5VMR1116-458RRR. doi: 10.1189/jlb.5VMR1116-458RRR. [Epub ahead of print] Review.

PMID:
28546500
18.

Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy.

Baniyash M.

Cancer Immunol Immunother. 2016 Jul;65(7):857-67. doi: 10.1007/s00262-016-1849-y. Epub 2016 May 25. Review.

PMID:
27225641
19.

The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.

Tobin RP, Davis D, Jordan KR, McCarter MD.

J Leukoc Biol. 2017 Feb 8. pii: jlb.5VMR1016-449R. doi: 10.1189/jlb.5VMR1016-449R. [Epub ahead of print] Review.

PMID:
28179538
20.

Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases: Angel or Demon?

Su Z, Ni P, Zhou C, Wang J.

Scand J Immunol. 2016 Nov;84(5):255-261. doi: 10.1111/sji.12473. Review.

PMID:
27541573

Supplemental Content

Support Center